Pharmaceutical Composition Comprising Pimobendan
0 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to novel solid formulations comprising as pharmaceutically active compound pimobendan and to processes for producing such solid formulations. The invention furthermore relates to a method for manufacturing a medicament for the prevention and/or treatment of congestive heart failure, wherein the solid formulations according to the invention are used.
26 Citations
30 Claims
-
1-12. -12. (canceled)
-
13. A fluid-bed granulation process, comprising the steps of:
-
a) spraying an aqueous solution of pimobendan and a binder onto a solid support comprising one or several carriers or excipients, flavor and citric acid anhydride and b) drying the sprayed mixture; c) sieving and de-agglomerating the dried mixture; d) adding a flow regulator to the resulting mixture; e) adding a lubricant to the resulting mixture; and f) blending the resulting mixture for uniformity of granules. - View Dependent Claims (14, 15, 16)
-
-
18. A method of treating congestive heart failure in a small mammal, comprising:
administering a therapeutically effective amount of a solid formulation to a small mammal in need thereof, wherein the solid formulation comprises a homogenous dispersion of pimobendan or a pharmaceutically acceptable salt thereof; a polyvalent acid selected from the group consisting of citric acid, tartaric acid, an anhydride thereof and mixtures thereof, and; a flavor suitable for small animals, wherein the flavor is present in an amount of 5 to 30 percent by weight of said solid formulation. - View Dependent Claims (19, 20, 21, 22, 23, 24, 25, 26)
-
27. A method of treating congestive heart failure in a small mammal, comprising:
administering a therapeutically effective amount of a solid formulation to a small mammal in need thereof, wherein the solid formulation comprises a homogenous dispersion of pimobendan or a pharmaceutically acceptable salt thereof; a polyvalent acid selected from the group consisting of citric acid, tartaric acid, an anhydride thereof and mixtures thereof, wherein the polyvalent acid is present in an amount of 2.5 to 10 percent by weight of said solid formulation; starch in an amount of 25 to 50 percent by weight of said solid formulation; lactose in an amount of 25 to 50 percent by weight of said solid formulation; and a flavor suitable for small animals, wherein the flavor is present in an amount of 5 to 30 percent by weight of said solid formulation. - View Dependent Claims (28, 29, 30)
Specification